Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Sandhu, Karamjeet S. [1 ]
Quy Huynh-Tran [1 ]
Cooper, Elise Elise [1 ]
Zhang, Jianying [2 ]
Palmer, Joycelynne [2 ]
Tsai, Ni-Chun [2 ]
Thomas, Sandra [3 ]
Robbins, Marjorie [3 ]
Aribi, Ahmed [1 ]
Salhotra, Amandeep [1 ]
Mei, Mathew [1 ]
Cai, Ji-Lian [4 ]
Spielberger, Ricardo [4 ]
Koller, Paul [1 ]
Aldoss, Ibrahim [1 ]
Stein, Anthony [1 ]
Marcucci, Guido [1 ]
Budde, L. Elizabeth [1 ]
机构：
[1] City Hope Natl Med Ctr, Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Computat & Quantitat Med BRI, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Clin Translat Program Dev, 1500 E Duarte Rd, Duarte, CA 91010 USA
[4] Kaiser Permanente BMT Program, Los Angeles, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
ALL; acute lymphoblastic leukemia; blinatumomab; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ALL-440
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [1] Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Agrawal, Vaibhav
    Croslin, Cindy
    Beltran, Asuscena L.
    Zhang, Jianying
    Palmer, Joycelynne
    Quy Huynh-Tran
    Hernandez, Rochelle
    Thomas, Sandra
    Robbins, Marjorie
    Aribi, Ahmed
    Ali, Haris
    Stein, Anthony S.
    Budde, Elizabeth L.
    Al Malki, Monzr M.
    Marcucci, Guido
    BLOOD, 2022, 140 : 6235 - 6236
  • [2] Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/ Refractory (r/r) ALL
    Sandhu, Karamjeet S.
    Macias, Alan
    Del Real, Marissa
    Beltran, Asuscena L.
    Kim, Young Sun
    Zhang, Jianying
    Palmer, Joycelynne
    Robbins, Marjorie
    Loomis, Reyna
    Akhtari, Mojtaba
    Aribi, Ahmed
    Arslan, Shukaib
    Salhotra, Amandeep
    Mei, Matthew
    Pourhassan, Hoda
    Koller, Paul B.
    Amanam, Idoroenyi
    Agrawal, Vaibhav
    Curtin, Peter T.
    Spielberger, Ricardo
    Pullarkat, Vinod A.
    Aldoss, Ibrahim
    Stewart, F. Mark
    Smith, Eileen P.
    Forman, Stephen J.
    Stein, Anthony S.
    Marcucci, Guido
    Budde, L. Elizabeth
    BLOOD, 2022, 140 : 8985 - 8986
  • [3] Correlative Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/ Refractory (r/r) ALL
    Macias, Alan Daniel
    Sandhu, Karamjeet
    Del Real, Marissa M.
    Young, Kim
    Beltran, Asucena L.
    Ng, Kenneth
    Zhang, Jianying
    Palmer, Joycelynne
    Robbins, Marjorie
    O'Hearn, James
    Akhtari, Mojtaba
    Marcucci, Guido
    Budde, Lihua E.
    MOLECULAR THERAPY, 2023, 31 (04) : 30 - 31
  • [4] Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Kobayashi, Yukio
    Zimmerman, Zachary F.
    Oh, Iekuni
    Maeda, Yoshinobu
    Minami, Hironobu
    Miyamoto, Toshihiro
    Sakura, Toru
    Iida, Hiroatsu
    Chen, Yuqi
    Kiyoi, Hitoshi
    BLOOD, 2018, 132
  • [5] Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies.
    Kantarjian, Hagop M.
    Stein, Anthony Selwyn
    Bargou, Ralf C.
    Grande, Carlos
    Larson, Richard A.
    Stelljes, Matthias
    Benjamin, Jonathan Eliot
    Jia, Catherine
    Topp, Max S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study.
    Kantarjian, Hagop
    Goekbuget, Nicola
    O'Brien, Susan Mary
    Stein, Anthony Selwyn
    Jia, Catherine
    Forman, Stephen J.
    Bargou, Ralf C.
    Fielding, Adele K.
    Heffner, Leonard T.
    Larson, Richard A.
    Neumann, Svenja
    Maniar, Tapan
    Nagorsen, Dirk
    Topp, Max S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] BLINATUMOMAB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL): A PHASE 1/2 STUDY
    Whitlock, J.
    von Stackelberg, A.
    Handgretinger, R.
    Locatelli, F.
    Rizzari, C.
    Trippett, T.
    Borkhardt, A.
    O'Brien, M.
    Rheingold, S.
    Gore, L.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S138 - S138
  • [8] Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Ziegler, David S.
    Huynh, Van
    Burke, Michael J.
    Gore, Lia
    Locatelli, Franco
    O'Brien, Maureen M.
    Kim, Christopher
    Obreja, Mihaela
    Morris, Christopher L.
    Baruchel, Andre
    BLOOD, 2021, 138
  • [9] INFLUENCE OF BASELINE FACTORS ON OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) TREATED WITH BLINATUMOMAB
    Topp, M. S.
    Goekbuget, N.
    O'Brien, S.
    Stein, A.
    Jia, C.
    Forman, S. J.
    Bargou, R.
    Fielding, A. K.
    Heffner, L. T., Jr.
    Larson, R. A.
    Neumann, S.
    Maniar, T.
    Nagorsen, D.
    Kantarjian, H.
    HAEMATOLOGICA, 2015, 100 : 30 - 30
  • [10] Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
    Sanchez, Pilar Martinez
    Zugmaier, Gerhard
    Gordon, Paul
    Jabbour, Elias
    Roca, Jose J. Rifon
    Schwartz, Stefan
    Borlenghi, Erika
    Huguet, Francoise
    Hernandez-Rivas, Jesus Maria
    Lussana, Federico
    Berthon, Celine
    Kadu, Priti
    Wong, Hansen
    Markovic, Ana
    Katlinskaya, Yuliya
    Rambaldi, Alessandro
    BLOOD, 2022, 140 : 6122 - 6124
12345